Добро пожаловать
Зарегистрировать аккаунт
Войдите, используя email
Зарегистрируйтесь с помощью email
Проверь свои входящие
Schrödinger
About
Schrödinger develops molecular design software for pharma/biotech and materials research, and is advancing a drug discovery pipeline.
- New York,New York,United States
- 501 - 1000
- http://www.schrodinger.com
Details
- Last Funding Type
- Post-IPO Equity
- Last Funding Money Raised
- $346.50M
- Industries
- Biotechnology,Enterprise Software,Pharmaceutical,Software
- Founded date
- Aug 16, 1990
- Number Of Employee
- 501 - 1000
- Operating Status
- Active
- Stock Symbol
- nasdaq:SDGR
- Legal Name
- Schrödinger, Inc.
Schrödinger’s industry-leading computational platform facilitates the research efforts of biopharmaceutical and industrial companies, academic institutions and government laboratories worldwide. Schrödinger also has wholly-owned and collaborative drug discovery programs in a broad range of therapeutic areas.Schrödinger is deeply committed to investing in the science and talent that drive its computational platform. Schrödinger was founded in 1990, has over 700 employees and is engaged with customers and collaborators in more than 70 countries. To learn more visit www.schrodinger.com.
Funding Rounds
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Nov 18, 2021 | Grant | $4.90M | 1 |
Bill & Melinda Gates Foundation
|
— | Detail |
| Aug 10, 2020 | Post-IPO Equity | $346.50M | — | — | — | Detail |
| Feb 5, 2020 | IPO | $232M | — | — | — | Detail |
| May 19, 2019 | Series E | $25M | 5 | — | — | Detail |
| Apr 1, 2019 | Series Unknown | — | 1 | — | — | Detail |
Investments
|
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
|---|---|---|---|---|
|
Feb 1, 2022
CertifyOS
|
Seed | $4.55M | — | |
|
Nov 19, 2021
Shyft
|
Seed | ₹450M | Fitness | — |
|
Oct 20, 2021
Structure Therapeutics
|
Series B | $100M | Biotechnology | — |
|
Jun 1, 2021
Ajax Therapeutics
|
Series Unknown | $40M | Biotechnology | — |
|
Jul 21, 2020
Vegrow
|
Seed | $2.50M | Agriculture | — |
Investors
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
|
Bill & Melinda Gates Foundation
|
Yes | Grant |
WuXi AppTec
|
Yes | Series E |
Bill Gates
|
Yes | Series C |
Cascade Investment
|
Yes | Series B |
David E. Shaw
|
Yes | Series A |
Invus
|
— | Series E |
Laurion Capital Management
|
— | Series E |
Michael Antonov
|
— | Series E |
Pavilion Capital
|
— | Series E |
|
|
— | Series E |
Employee Profiles
Exits
Schrödinger has had 3 exits. Schrödinger most notable exits include Structure Therapeutics , Nimbus Therapeutics
| Date | Company Name | Exit Type | Industry | |
|---|---|---|---|---|
| Feb 2, 2023 | Structure Therapeutics | IPO | Biotechnology | Detail |
| Dec 14, 2022 | Nimbus Therapeutics | M&A | Biotechnology | Detail |
| Jun 27, 2019 | Morphic Therapeutic | IPO | Biotechnology | Detail |
Acquisition
Schrödinger has acquired 1 organizations. Their most recent acquisition was Xtal BioStructures on Jan 18, 2022. They acquired Xtal BioStructures for $6M.
|
Date
Company Name
|
Industry | Acquisition Type | Price | |
|---|---|---|---|---|
|
Jan 18, 2022
Xtal BioStructures
|
Biotechnology | acquisition | $ 6M | Detail |
